Skip to content
Back to catalogue
PT-141 pen, black
PT-141 pen, pink

Libido & intimacy

PT-141

Acts through the brain, not the blood vessels

Format

Add a refill for your pen

PT-141 10 mg · +AED 745 each

0

Quantity — buy more, save more

Other quantity

1

Any mix counts: items from other products add up too.

PriceAED 790

Frequently paired with

Tap Add — each one counts toward your bundle saving.

Kisspeptin 10 mg

AED 730

Add another item from the catalogue

Pens are added as the reusable pen; change the format on the product page if you prefer.

A melanocortin-receptor agonist that acts centrally rather than on blood flow. Studied for its effect on the brain's desire pathway in both male and female models.

Research use only. Supplied for laboratory and analytical research. Not a medicine or supplement, and not for human or animal use. We don't give dosing or clinical advice. Read the terms

Presentation
Lyophilised powder, reconstituted — 3 mL pen

Manufactured under controlled research-grade conditions. For documentation or questions about this compound, contact us on WhatsApp.

Published research

  1. Human trial

    In healthy men and men with mild-to-moderate erectile dysfunction, intranasal PT-141 produced erectile responses greater than placebo and was generally well tolerated; flushing and nausea were most common.

    Diamond LE, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research. 2004. PMID 14963471

  2. Human trial

    In a randomised placebo-controlled dose-finding trial in premenopausal women with sexual dysfunction, bremelanotide improved sexual function and distress scores; nausea, flushing and headache were the main adverse events.

    Clayton AH, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's Health (London). 2016. PMID 27181790

  3. Human trial

    In two phase 3 trials in premenopausal women with hypoactive sexual desire disorder, bremelanotide (PT-141) improved desire and reduced related distress versus placebo; nausea, flushing and headache were more common.

    Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019. PMID 31599840

  4. Animal study

    In female rats, PT-141 selectively increased sexual solicitation behaviours without affecting other sexual behaviours, general activity or the perception of sexual reward.

    Pfaus JG, et al. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences of the USA. 2004. PMID 15226502

  5. Review

    This overview by the developer reports that PT-141, a synthetic alpha-MSH analogue acting at MC3R and MC4R, produced penile erections in rats and nonhuman primates and a dose-dependent increase in erectile activity in healthy men and men with erectile dysfunction.

    Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences. 2003. PMID 12851303

Short summaries of published studies, with links to the original papers. Results in animals or cells may not apply to people. This is not medical advice and not a guide to use.

All research on PT-141